Assessing the Risk of Birth Defects Associated with Exposure to Fixed-Dose Combined Antituberculous Agents during Pregnancy in Rats

Table 1

Incidence of resorption and live foetus in treated rats.

Groups	Stage of drug exposure	Percentage (%) of live foetus	Average number of live foetus	Number of resorption
Group 1	Organogenesis	100	7.33±0.023	0
Group 2	Organogenesis	100	8.33±0.43	0
Group 3	Organogenesis	100	8.00±0.00	0

Group 1: control group. Group 2: administered with clinical dose (51.4 mg/kg/day) of fixed-dose combined antituberculous agents. Group 3: administered with clinical dose of fixed-dose combined antituberculous agents plus 10 mg/kg/day of Vitamin C.